IP Library Granted Patent US 10,400,029
Granted Patent B2
US 10,400,029 · App. 14/524,832 · Granted Sep 3, 2019

Serpin fusion polypeptides and methods of use thereof

Inventors: Brendan P. Eckelman (La Jolla, CA); John C. Timmer (La Jolla, CA); Quinn Deveraux (La Jolla, CA)
Assignee: Inhibrx, LP
C07K14/8125C07K14/525C07K14/7151C07K14/7155C07K14/811C07K14/8121C07K16/241A61K38/00C07K2317/53C07K2317/72C07K2317/94C07K2319/00C07K2319/30C07K2319/31C07K2319/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,400,029
App. No.
14/524,832
Granted
Sep 3, 2019
Kind
B2
Abstract

This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.

Claims (10)

1. An isolated fusion protein comprising at least one human serpin polypeptide operably linked to a modified human immunoglobulin Fc polypeptide, wherein the modified human immunoglobulin Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 60, wherein the immunoglobulin Fc polypeptide comprises mutations at positions S228, L235, M252, and M428, and wherein the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide comprising the amino acid sequence of SEQ ID NO: 80.

2. The isolated fusion protein of claim 1 , wherein the fusion protein further comprises an additional polypeptide selected from the group consisting of:

a cytokine targeting polypeptide;

a whey acidic protein (WAP) domain containing polypeptide; or

an albumin polypeptide.

3. The isolated fusion protein of claim 1 , wherein the AAT polypeptide comprises a mutated reactive site loop of AAT comprising the amino acid sequence of SEQ ID NO: 32.

4. The isolated fusion protein of claim 1 , wherein the mutations at positions S228, L235, M252, and M428 comprise S228P, L235E, M252Y, and M428L.

5. The isolated fusion protein of claim 1 , wherein the AAT polypeptide and the immunoglobulin Fc polypeptide are operably linked via a hinge region, a linker region, or both a hinge region and linker region.

6. The isolated fusion protein of claim 5 , wherein the hinge region, the linker region or both the hinge region and the linker region comprise a peptide sequence.

7. An isolated fusion protein comprising at least one human serpin polypeptide operably linked to a modified human immunoglobulin Fc polypeptide, wherein the modified human immunoglobulin Fc polypeptide comprises the amino acid sequence of SEQ ID NO:73, and wherein the human serpin polypeptide is a human alpha-1 antitrypsin (AAT) polypeptide comprising the amino acid sequence of SEQ ID NO: 80.

Assignments (5)
CHANGE OF NAME Recorded Aug 22, 2024
From: INHIBRX, INC.
To: SANOFI AATD INC.
Reel/Frame 068752/0666 →
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2022
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 059253/0430 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2017
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 043195/0189 →
Continuity (6)
Continuation In Part 13536976 · Jun 28, 2012
Provisional Application 61638168 · Apr 25, 2012
Provisional Application 61577204 · Dec 19, 2011
Provisional Application 61570394 · Dec 14, 2011
Provisional Application 61502055 · Jun 28, 2011
Related Publication 20150104410A1 · Apr 16, 2015
Cited By (1)
US 12,497,441